GSK Must Face Mylan's Breach Of Contract Suit For Authorized Generic Paxil

GSK Must Face Mylan's Breach Of Contract Suit For Authorized Generic Paxil

PHILADELPHIA - A federal appeals court on July 22 reversed summary judgment in favor of GlaxoSmithKline LLC (GSK) in a lawsuit in which generic drug maker Mylan Inc. claims that GSK breached a contract to allow Mylan to market a generic version of the antidepressant Paxil by allowing another drug maker to do the same (Mylan Inc., et al. v. SmithKline Beecham Corporation, et al., No. 12-1539, 3rd Cir.).

Access this news story on lexis.com®